QUOTE (Pudge @ Mar 19 2006, 01:38 AM)

Thanks to all who answered my post re: Fosamax. I am so confused and do not know what to do. should i stop taking it? or continue.....again my dr. said i have osteopenia.....and i should take the lowest dose......so far no side effects but i am not one to take meds so i was reluctant from the beginning. It seems like i have not heard anything good about this drug. I have been on it for about two months now. Is it okay to just stop taking it......What should i do.........any comments are appreciated......Help, I am soo confused. thanks Pudge
Hello Pudge,
My vote is still the same. Stop taking this type of drug immediately. Read all of the posts again. Check out all of the websites, and check out the other message boards on this Power Surge site, such as "Fosamax, anyone taking this?".
Also, take heed of this warning specifically for Boniva (but applicable for all bisphosphonates, including Fosamax) which I believe was added in 2005 by the FDA:
307 Jaw Osteonecrosis
308 Osteonecrosis, primarily in the jaw, has been reported in patients treated with
309 bisphosphonates. Most cases have been in cancer patients undergoing dental procedures,
310 but some have occurred in patients with postmenopausal osteoporosis or other diagnoses.
311 Known risk factors for osteonecrosis include a diagnosis of cancer, concomitant therapies
312 (e.g., chemotherapy, radiotherapy, corticosteroids), and co-morbid disorders (e.g.,
313 anemia, coagulopathy, infection, pre-existing dental disease). Most reported cases have
314 been in patients treated with bisphosphonates intravenously but some have been in
315 patients treated orally.
316 For patients who develop osteonecrosis of the jaw (ONJ) while on bisphosphonate
317 therapy, dental surgery may exacerbate the condition. For patients requiring dental
318 procedures, there are no data available to suggest whether discontinuation of
319 bisphosphonate treatment reduces the risk of ONJ. Clinical judgment of the treating
320 physician should guide the management plan of each patient based on individual
321 benefit/risk assessment.
V3.13
11
322 Musculoskeletal Pain
323 In postmarketing experience, severe and occasionally incapacitating bone, joint, and/or
324 muscle pain has been reported in patients taking bisphosphonates that are approved for
325 the prevention and treatment of osteoporosis (see ADVERSE REACTIONS). However,
326 such reports have been infrequent. This category of drugs include BONIVA (ibandronate
327 sodium) Tablets. Most of the patients were postmenopausal women. The time to onset of
328 symptoms varied from one day to several months after starting the drug. Most patients
329 had relief of symptoms after stopping. A subset had recurrence of symptoms when
330 rechallenged with the same drug or another bisphosphonate.
Kindest regards,
Momkat